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Sera from patients with rheumatoid arthritis (RA) 1 often contain rheumatoid 
factor(s) (RF), antibodies that bind to the Fc portion of IgG. Hannestad, Johan- 
nesson, and Stoilar (1,  2) isolated monoclonal and polyclonal RF from human 
sera, which not only bound IgG but also were antinuclear antibodies specific for 
nucleohistone (1,  2).  Subsequently cross-reacting autoantibodies with both RF 
and anti-histone activity were isolated from sera of- 10% of RA patients (3), and 
considerably higher incidences were suggested by other reports (4-7). RF with 
anti-histone activity appear to possess an idiotype that is distinct from the idiotype 
of RFs without anti-histone activity (5). 
Sporadic reports of RF with other activities have appeared.  Hannestad  (8) 
described a RF with ability to bind nitrophenyl groups and dDNA. Cunliffe and 
Cox  (9)  detected mouse RF that  bound isologous IgG as  well as bromelain- 
treated erythrocytes. 
The interpretation of these provocative findings is not unambiguous. Since 
these RF  were part of the serum antibody, it  is not possible to establish the 
monoclonal nature of the antibodies presumed to have multiple specificities. It 
is also difficult to exclude the presence of IgG with antinuclear activity which is 
bound to RF autoantibodies, a complex demonstrated in sera from MRL/I mice 
(10). The availability of cross-reacting monoclonal IgM-RF produced in tissue 
culture would overcome these objections, since contamination by IgG antibodies 
would be excluded. 
We recently obtained 23  mouse hybridomas producing RF by selection for 
IgM antibody to mouse IgG (11). These hybrids were derived from MRL/lpr 
mice,  a  lupus  strain  whose  natural  history  includes  production  of  RF  and 
polyarthropathy resembling human RA (I 2).  The present report describes the 
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capacity  of some  of these  monoclonal  RF  to  bind  multiple  autoantigens  in 
addition to IgG. 
Materials and Methods 
The  origin  and  characteristics  of the  hybridomas  producing  monoclonal  RF,  the 
radioimmunoassay  for RF, and the methodology for aggregating mouse IgG have been 
described (11). 
The enzyme-linked  immunosorbent assays (ELISA)  were performed  using  antigens 
immobilized onto Immulon 2 microtiter plates (Dynatech Laboratories, Alexandria,  VA) 
at -2 #g/ml in phosphate-buffered saline (PBS), pH 7.2 and obtained from the following 
sources: total histones and heat-denatured DNA (dDNA) (Ca!biochem-Behring  Corp., La 
Jolla,  CA), mouse IgG subclasses (Litton Bionetics, Kensington,  MD), re-purified prom- 
mines,  polyuridylic  acid (Poly  U) and  polyinosinate  (Poly I) (Sigma Chemical  Co.,  St. 
Louis, MO), polylysine and polyarginine (Miles Laboratories, Eikardt,  IN), polycytidylic 
acid (poly C), polyadenylic acid (poly A), polydeoxyadenylic acid (poly dA) (P-L Biochem- 
icals, Milwaukee, WI). Individual  histones  were purified from calf thymus chromatin by 
the method of Bohm et al. (13) and their purity was >95% as assessed by polyacrylamide 
gel electrophoresis as previously described (14). The assays were performed as previously 
reported  (15)  using  monoclonai  antibody preparations  isolated  by ammonium  sulfate 
precipitation  of hybridoma culture fluid. 
Affinity  purification  of antibody preparations  was performed with  various  antigens 
immobilized  in microtiter plates.  Antibody was diluted in standard ELISA solvent and 
incubated in replicate antigen-coated wells. After appropriate washes, antibody was eluted 
by incubation at room temperature in a solution consisting of 0.1  N NH4OH, 1 mg/mi 
BSA, 0.05% Tween-20 (pH 10.9) for 1.5 h. The eluates were pooled and neutralized by 
the addition of phosphate buffer and HCI and assayed as described above. 
The mouse IgM concentration  in each monoclonal  antibody preparation  was deter- 
mined by ELISA using  wells coated with  affinity-purified  anti-mouse  immunoglobulin 
(polyvalent,  Tago,  Inc.,  Burlingame,  CA). A  parallel  set  of wells was incubated with 
increasing  concentrations of a mouse myeloma IgM (MOPC 104E,  Litton Bionetics) in 
order to generate a standard curve. The IgM concentration in an antibody preparation 
was estimated from the standard curve after appropriate correction for dilution. 
lmmunofluorescence studies were performed using Hep-2 cells (Bion, Ridge, IL) or a 
rabbit kidney cell line (Electro-Nucleonics,  Bethesda, MD) grown and fixed on microscope 
slides. Antibody preparations  were diluted  in  PBS and  25  #1 was incubated  with  the 
substrate for 1 h at room temperature. After appropriate washes, fluorescein-conjugated 
F(ab')2 anti-mouse  IgM (Cappel Laboratories, Cochranville, PA) was added and incubated 
for 30 min. Positive cells were visualized by fluorescence microscopy. 
Results 
Anti-DNA and Anti-histone Activities of  Monoclonal RF.  Mouse hybridomas were 
selected for secretion of IgM RF as previously described (11). Antibody produced 
in tissue culture from these hybridomas was concentrated by ammonium sulfate 
precipitation  and  tested  for  binding  to  total  histones  and  dDNA  by ELISA. 
Monoclonal RF (mRF) that were reactive with either dDNA or histone, as well 
as their binding to IgG subclasses, are shown in Table I. Of the 23 mRF, three 
displayed highly elevated binding to dDNA and one was weakly, but significantly, 
reactive. Two mRF bound histones and one of these (mRF7) was also a  dDNA 
reactor. 
The antibodies that displayed anti-histone activity were assayed for binding to 
individual histories and basic polypeptides, as shown in Table II. Clone 7 bound 
histones  HI  and  H4  predominantly,  as  well  as  polylysine,  polyarginine,  and RUBIN  ET  AL. 
TABLE  I 
Antigen Binding Specificities of Multireactive Monoclonal Antibodies* 
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IgM bound to test antigen: 
Clone  ug IgM/ml  OD 
IgG1  IgG2a  IgG2b  IgG3  Total histone  dDNA 
mRF7  0  0  14.5  0  2.3  16.7 
mRFI6  4.4  4.3  0  1.3  6.7  0 
mRF20  0.5  0.3  0.4  0.5  0  6.2 
tuRF21  2.7  3.5  3.2  4.6  0  5.8 
mRF18  4.1  2.2  1.5  8.7  0.1  0.6 
A total of 23 stable monoclonal antibodies selected for binding to mouse IgG 
were produced (11). Shown above are the five clones that were reactive with 
total histones, individual histones, or dDNA at a  200-fold dilution of tissue 
culture supernatant concentrated by ammonium sulfate precipitation. The anti- 
IgG activity was  determined by RIA and  the  anti-histone and anti-dDNA 
activities were assayed by ELISA. 
TABLE  II 
Reactivity of Histone-Binding  mRF with Various Histone Classes and Basic Polypeptides* 
IgM bound to test antigen (OD) 
Clone 
H1  H2A  H2B  H3  H4  Polylysine  Polyarginine  Protamines 
tuRF7  12.1  0.1  1.1  0.8  9.2  11.9  4.6  3.6 
mRF16  0  17.3  0  0  >22  0  0  0 
* Concentrated tissue culture supernatants from hybridoma clones 7 and 16 were diluted 100-fold 
and tested for reactivity with various antigens. With the exception of mRF21, which had a weak 
reaction with histone H 1, none of the other tuRF displayed reactivity with any of the individual 
histones. 
TABLE  [II 
Reactivity of dDNA-binding tuRF with Various Polynucleotides* 
IgM bound to test antigen (OD) 
Clone 
dDNA  Poly(dA)  Poly(A)  Poly(T)  Poly(I)  Poly(U)  Poly(C) 
mRF7  7.4  0  0  0  6.1  0  0 
tuRF18  0.1  0  0.2  0.1  0.1  0  0 
tuRF20  1.9  0  0  1.8  2.1  0  0 
tuRF21  1.5  0  0.5  2.4  0  O  0 
* Binding to polynucleotides was determined at an IgM concentration of 6 #g/ml for mRF7 and 
mRF21, and at 0.6  ~g/ml for tuRF20  due to its limited supply. The binding of tuRF18  was 
negligible at 6 ~g/ml and results at 60 #g/ml are shown above. Five other tuRF tested, including 
tuRF 16, did not bind to any polynucleotide at 60 ~g/ml. 
protamines.  Clone  16  also  bound  H4  but  differed  from  mRF7  in  displaying 
binding to H2A  and to no other histone or basic polypeptide. 
The  four  mRF  with  anti-dDNA  activity  were  examined  for  reactivity  with 
synthetic polynucleotides.  Each  monoclonal  displayed a  unique  binding profile 
with  the  six polynucleotides tested  (Table  III). Clone tuRF20  bound  to poly(I) 
and poly(T), whereas mRF21  did not interact with poly(I) but displayed affinity 
for poly(A) and poIy(T). Clone tuRF7 bound  onIy to poly(I). In contrast, tuRF18 1432  CROSS-REACTING  RHEUMATOID  FACTORS 
showed weak binding to poly(A), poly(I), and poly(T). It appears, therefore, that 
the mRF that displayed cross-reactions with dDNA  have subtle but significant 
differences in their polynucleotide binding specificities. 
Monomolecular Nature of the Multiple Activities of tuRF7 and mRF16.  The hybri- 
domas were grown under conditions that should insure monoclonality, and this 
was supported by the observation that upon subcloning each well containing a 
growing clone had the entire spectrum of antibody activities. In addition direct 
proof was sought that the multiple reactivities of each tuRF preparation resided 
in the same molecule. Six serial adsorptions of tuRF7 in mouse IgG-coated wells 
resulted in sequential, concomitant loss of 82% of the anti-histone activity. As a 
control for nonspecific loss of antibody, an IgM monoclonal antibody to dDNA, 
which was devoid of RF activity, was subjected to adsorption by mouse IgG, but 
no loss of anti-DNA activity was observed. 
To further substantiate that the multiple reactivity of the antibody preparations 
resided within a single population, antibodies that were affinity purified on each 
cross-reacting antigen were examined for their binding specificities. Fig. 1 shows 
the antibody activities of three affinity-purified preparations of mRF 16. Antibody 
eluted  from  H4-coated  wells  displayed  reactivity  with  H4,  H2A,  and  most 
importantly, mouse IgG. Similar binding properties were observed with the H2A 
eluate.  Of greatest importance was the observation that antibody eluted from 
mouse IgG-coated wells bound histones H4 and H2A. It appears, therefore, that 
mRF16 antibody affinity purified on each  relevant antigen  displayed binding 
properties that resembled those of the untreated preparation. 
Fig. 2 shows the results of a similar experiment using tuRF7. Five preparations, 
affinity  purified  on  HI,  polylysine,  H4,  IgG2b,  and  dDNA,  were  tested  for 
binding to all these antigens. With each antigen used for immunoadsorption, the 
eluted antibodies displayed similar antigen binding profiles, indicating that the 
same antibody population was isolated regardless of the antigen used for affinity 
purification. 
Evaluation of Multiplicity of Molecular Interactions by Inhibition Studies.  Of the 
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FIGURE  1.  Reciprocal  cross-reactions  of affinity-purified  mRFI6.  Hybridoma  antibodies 
produced  in  tissue  culture  were  bound  to  histones  H4  or  H2A  or  to  mouse  IgG  and 
subsequently eluted from the solid phase antigen. The capacity of each eluate to bind H4 and 
H2A  was  tested  by  ELISA,  and  the  binding to  mouse  IgG  was  assessed  by  solid  phase 
radioimmunoassay. RUBIN  ET  AL.  1433 
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FIGURE 2.  Reciprocal cross-reactions of affinity-purified tuRF7. Hybridoma antibodies pro- 
duced in tissue culture were bound to H4, H 1, polylysine, IgG2b, or dDNA. Antibody was 
subsequently eluted from each solid phase antigen. The capacity of each eluate to bind the 
relevant antigens was determined by ELISA. 
five multi-reactive monoclonal RF, mRF7 possessed  the most complex antigen 
binding properties. By examining the ability of mRF7 to bind to dDNA or IgG2b 
in the presence of various soluble antigens~ we sought to obtain some insight into 
the molecular basis of this phenomenon. 
Inhibition studies involving different classes of histones could not be performed 
because of the strong tendency for histones to interact with various antigens, 
including polyanions such as DNA, IgG at histone concentrations above 10 #g/ 
ml (unpublished observations), and self associations (histone-histone interactions). 
As a result of these secondary interactions, competition studies are hampered 
and commonly show enhancement of binding rather than inhibition. Therefore, 
the relationship between the histone binding site and the DNA and IgG binding 
sites could not be ascertained. However, inhibition studies were possible  with 
DNA, IgG, and polynucleotides where such secondary interactions do not occur 
under appropriate conditions. 
Fig. 3 shows the ability of various nucleic acids and of aggregated IgG2b to 
affect the binding of tuRF7 to solid-phase dDNA. Inhibition of 90% of the anti- 
dDNA activity of mRF7 was achieved with 0.02 ug/ml poly(I), 0.2 t~g/mi dDNA, 
and 2 #g/ml aggregated IgG2b. No effect of poly(A) at the highest concentration 
used (50 #g/ml) was observed, consistent with the absence of detectable direct 
binding to poly(A) (Table III). The corollary experiment, that is the capacity of 
various soluble proteins and polynucleotides to inhibit the binding of tuRF7 to 
lgG2b, is shown in Fig. 4. Aggregated IgG2b, the homologous antigen, blocked 
50%  of the antibody binding at 0.25 t~g/ml and 90%  at  1 #g/ml.  Poly(I) and 
dDNA were even more potent competitors on a weight basis,  displaying 50% 
inhibition ofanti-IgG2b activity at <0.006 #g/ml and <0.02 ug]ml, respectively, 
and approaching complete inhibition at ~0.5 #g/ml. Poly(A) had only a slight 1434  CROSS-REACTING  RHEUMATOID  FACTORS 
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FIGURE 3.  Inhibition  ofanti-dDNA activity of mRF7 by various antigens. Increasing concen- 
trations of poly(I), poly(A), dDNA, or IgG2b were added to mRFT, and the mixtures were 
immediately plated into wells coated with dDNA and subjected to the standard ELISA. 
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FIGURE 4.  Inhibition of RF activity (anti-IgG2b) of tuRF7 by various antigens. Increasing 
concentrations of poly(I), poly(A), poly(U), dDNA, or lgG2b were added to tuRF7, and the 
mixtures were immediately plated into wells coated with IgG2b and subjected to the standard 
ELISA. 
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inhibitory effect on the anti-IgG2b activity at  50  pg/ml.  However, poly(U), a 
polynucleotide for which we did not detect binding of mRF7 by direct ELISA, 
inhibited anti-IgG2b activity at a  concentration >5  #g/ml and brought about 
50% inhibition at 12 #g/ml. It should be noted that since the molecular weights 
and valencies of the various inhibitors are unknown, their potency as inhibitors 
cannot be used to accurately estimate their relative binding affinities. 
As indicated above,  H4  showed non-specific binding  to immobilized mouse 
immunogiobulins, thereby limiting inhibition studies with this antigen. Below 10 
#g/rot H4 did not block anti-IgG2b activity of mRF7. RUBIN  ET  AL.  1435 
As shown in Table III, mRF20 and mRF21 displayed strong binding to dDNA. 
Table IV shows that the RF activities of both tuRF20 and tuRF21 were blocked 
by increasing concentrations of soluble dDNA. The anti-IgG activity of tuRF8, 
an  antibody  that  did  not  have  anti-dDNA  activity,  was  not affected by  the 
presence of dDNA up to 50 #g/ml. 
lmmunofluorescence  Studies.  The 23 tuRF were tested for binding to intracel- 
lular antigens in fixed Hep-2 cells, as detected microscopically using a fluorescein- 
conjugated anti-mouse IgM. Nine of these tuRF displayed immunofluorescence 
staining, and representative patterns are shown in Fig. 5. A cytoplasmic filamen- 
tous staining was displayed by mRF4,mRF5, tuRF 18, and tuRF21; the latter two 
antibodies also gave an underlying "ground glass"  or fine speckled staining in 
the cytoplasm. It is unlikely that binding of these mRF to what appears to be 
intermediate filaments (16) was nonspecific or mediated through the Fc region 
of IgM, because 19 of 23 mRF at similar concentrations and an IgM myeloma 
protein at 250 #g/ml did not bind cytoskeletal components. 
A speckled pattern of cytoplasmic fluorescence was displayed by tuRF20 and 
tuRF7, the latter showing fluorescence that tended to concentrate around the 
periphery of the nucleus. Nuclear and chromosomal staining was displayed by 
tuRF16, presumably due to its anti-histone activity.  Monoclonals mRF10 and 
mRF11  bound to  structures in  the cytoplasm of Hep-2  cells that  resembled 
discontinuous thick fibers or rods. These structures appear to be mitochondria 
by the presence of stained spherically shaped organdies (as expected for mito- 
chondria) in a cell line derived from rabbit kidney. 
As previously shown, mRF7, tuRF18,  tuRF20,  and mRF21  possessed anti- 
dDNA activity and the capacity to bind a variety of homopolynucleotides  (Table 
III).  Therefore, the effect of pre-incubating these antibodies with dDNA on 
their intraceltular staining properties was examined. Absorption with 10 #g/ml 
dDNA  significantly  reduced  staining  of all  these  tuRF  except  mRF21  and 
completely blocked immunofluorescence  at 50 t~g/ml. It appears, therefore, that 
the speckled cytoplasmic staining properties of mRFT, tuRF18, and mRF20 are 
closely related to their anti-dDNA activities. However, the staining of the non- 
anti-dDNA tuRF (mRF 4, 5,  10,  11, and 16) was not affected by dDNA up to 
50 ~g/ml. 
TABLE  IV 
Effect of dDNA on Binding of mRF to Mouse IgG* 
dDNA #g/ml 
Anti-IgG (% of control) 
mRF20  tuRF21  mRF8 
0  100  100  100 
1  102  46  100 
10  31  5  88 
50  8  3  111 
* Increasing concentrations of dDNA were mixed with each preparation 
of diluted mRF, and the mixture was assayed for binding to a pool of 
mouse  IgG myeloma proteins.  Monoc|onals tuRF20  and  tuRF21  dis- 
played anti-dDNA, whereas tuRF8 did not. 1436  CROSS-REACTING  RHEUMATOID  FACTORS 
FIGURE 5.  Binding of various mRF to intracellular antigens as assessed by indirect immu- 
nofluorescence. Each preparation was diluted to -60 #g IgM/ml and incubated with Hep-2 
cells grown and fixed onto microscope slides. Antibody binding was revealed by a fluorescein- 
conjugated F(ab')2 anti-mouse IgM at 500X original magnification. The staining of mRFI0 is 
shown on a  cell  line derived  from  rabbit kidney as well as on Hep-2  cells.  Not  shown are 
tuRF4, which appeared similar to tuRF5 and mRF11, which was similar to mRF10. RUB1N  ET  AL.  1437 
Discussion 
In this study we have described a number of tuRF from a lupus and arthritis 
animal  model (i.e.,  MRL/I  mice) that  cross-reacted  with a  variety  of cellular 
antigens.  Of the  23  hybridomas obtained,  ~~fi produced antibodies  that  had 
other activities in addition to the anti-IgG activity for which they were selected. 
The predominant cross-reactions were against histones and basic homopolypep- 
tides and against dDNA and homopolynucleotides. No two tuRF showed exactly 
the same profile of antigen binding specificities, indicating that each hybridoma 
originated from a different B cell. The relatively high incidence of cross-reacting 
tuRF is consistent with previous reports on cross-reacting polyclonal RF from 
human sera (1-8) and provides strong support for the existence of such antibodies 
in patients with rheumatoid arthritis. Work in progress with human tuRF derived 
from RA and lupus patients has also demonstrated similar cross-reactions. 2 
Numerous reports of monoclonal antibodies and antibodies from polyclonal 
sources with capacity to bind more than one antigen have appeared. Mouse and 
human monoclonal antibodies selected for anti-DNA activity bound a variety of 
polynucleotides and phospholipids (17)  and  many of the  antibodies possessed 
cross-reactive idiotypes, even if derived from different mice (I 8) or humans (I 9). 
A monoclonal antibody was produced by Pillemer and Weissman (20) that bound 
Thy-1  antigen  on T  lymphocytes and  the  idiotypic determinant of TEPC-15 
myeloma protein. A  number of studies reported the production of monoclonal 
antibodies that bound microfilaments or intermediate filaments as well as other 
antigens with no known structural  homology (21-25).  Reports of monoclonal 
antibodies displaying cross-reactions between viral proteins and a nuclear antigen 
(26) or other intracellular components (27) have recently appeared. Antibodies 
from human sera with the capacity to bind dDNA and nitrophenyl groups have 
been  reported  (28).  In  rabbits  antibodies  were  raised  to  AMP  that  bound 
menadione and caffeine but not the much more structurally similar GMP (29), 
and to K-light  chain that cross-reacted with fl2-microglobulin (30).  Particularly 
relevant  to  the  present  report  are  studies  with  human  RF  with a  variety  of 
multiple specificities (1-8).  The  present  findings of multireactive  monoclonal 
antibodies produced in tissue culture with similar properties support the previous 
studies and may add impetus to the search for the immunochemical basis,  the 
pathological significance, and the genesis of such antibodies. 
Another aspect of the present studies that may be relevant to previous obser- 
vations concerns the immunofluorescence findings. The capacity of the polynu- 
cleotide binding mRF to display a ~ground-glass" pattern of cytoplasmic staining 
may be due to binding to RNA in ribosomes, since this activity was blocked by 
dDNA, a heterogenous polynucleotide that may consist of conformations of the 
phosphodiester backbone that cross-react with ribosomal RNA. The staining of 
cytoskeletal components by four other tuRF cannot be explained by any known 
antigen binding activity of these mRF. However, patients with certain autoim- 
mune diseases such as the CREST syndrome (32), Sj6gren's syndrome (33), and 
particularly, rheumatoid arthritis (34,  35), show a  high incidence of antibodies 
2 Theofilopoulos, A. N., R. L. Rubin, R. S. Baladeras, E. M. Tan, and F.J. Dixon. Specificities of 
human IgM  monoclonal rheumatoid factors  derived from patients with rheumatoid arthritis and 
systemic lupus erythematosus.  Manuscript in preparation. 1438  CROSS-REACTING  RHEUMATOID  FACTORS 
to cytoskeletal elements. The current observations raise the possibility that in 
human sera, RF activity and binding to cytoskeletal elements may be a property 
of the same antibody population. 
Inhibition studies are commonly used to gain insight into the nature of the 
interactions involved in antibodies exhibiting multiple reactivities. Using mRF7 
as a prototype of this phenomenon, we demonstrated that soluble dDNA blocked 
the lgG binding activity and that soluble, aggregated lgG  inhibited the anti- 
DNA activity. A similar result was observed with mRF20 and tuRF21 but not 
with control mRF that did not display anti-dDNA activity. Competition between 
DNA  and  IgG  suggests  that  a  single  region  or  two  regions  with  partially 
overlapping amino acid contacts in the antibody combining site are responsible 
for both activities. However, a combining site within an antibody with capacity 
to bind both IgG and dDNA is unexpected, since there is no apparent similarity 
in primary structure between the phosphodiester backbone of denatured DNA 
(the presumed determinant [31 ]) and a peptide within IgG2b. The affinity of the 
DNA-binding RF for polynucleotides with different nucleotide bases such as 
poly(I), poly(T), and poly(A) suggests that the nucleotide base is not the primary 
binding site,  but  that a  special conformation of the nucleic acid backbone is 
required to generate the epitope to which the antibody is directed. Recognition 
by a single region within the antibody combining site of two epitopes having no 
known similarity in primary structure, e.g., DNA and IgG or H4 and IgG, is 
generally explained by a conformational epitope presumed to be common to the 
cross-reacting antigens. 
Alternative  explanations  for  the  molecular  basis  underlying multireactive 
antibodies  have  been  proposed (36-38),  based  on  the  notion  that  antibody 
combining sites are considerably larger than that needed to be complementary 
to  a  single  epitope.  A  relatively  large  binding site  may  consist  of separate 
subregions with capacity to react with different epitopes. Antigens may display 
co-inhibition because of overlapping spatial requirements rather than the same 
amino acid contacts within the antibody combining site.  The present findings 
suggest that multireactive antibodies may not be uncommon and, therefore, may 
be of significance as a mechanism for generating antibody diversity. 
Summary 
We report that ~% of monoclonal rheumatoid factors produced by hybridomas 
derived from fusions of spleen cells from MRL/lpr/lpr mice with systemic lupus 
erythematosus (SLE)  and  arthritis  exhibited  multiple  reactivities  with  other 
autoantigens,  including dDNA,  histones,  and/or  cytoskeletal-cytoplasmic ele- 
ments. The patterns of reactivities of most of these clones differed, indicating 
that each had a separate B cell ancestor. Studies with eluted antibodies demon- 
strated  that  a  single  species  of antibody  molecules was  responsible  for  the 
observed multiple reactivities. Inhibition experiments suggested that an antibody 
combining site may be large enough to accommodate dissimilar epitopes. These 
findings may provide further insights into the generation and extent of antibody 
diversity as well as the etiopathogenesis of systemic autoimmune diseases. RUBIN  ET  AL.  1439 
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